Vitamin-K-antagonist phenprocoumon versus direct oral anticoagulants in patients with atrial fibrillation: a real-world analysis of German claims data.

ABSTRACT:

Objectives

Direct oral anticoagulants (DOACs) were introduced based on randomised controlled trials (RCTs) comparing them to vitamin-K-antagonist (VKA) warfarin. In Germany, almost exclusively phenprocoumon is used as VKA. RCTs with phenprocoumon being absent we analysed the benefits and harms of DOACs and phenprocoumon for patients with atrial fibrillation (AF) in a real-world setting.

Design

In a retrospective observational cohort study, claims data covering inpatient and outpatient care from 2015 to 2019 were analysed by Cox regression and propensity score matching (PSM).

Setting

Data from a group of small-sized to medium-sized health insurance companies in Germany.

Participants

We analysed datasets of 71 961 patients with AF and first prescription of phenpr

SUBMITTER: Warkentin L 

PROVIDER: S-EPMC9809214 | biostudies-literature | 2023 Jan

REPOSITORIES: biostudies-literature